• Increase font size
  • Default font size
  • Decrease font size

Trade Alert: Big News Pending for SIGA Technologies, Inc.

Print E-mail
By M.E.Garza   
Tuesday, 24 November 2009 03:00

BioMedReports has learned that shares of this bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents, such as smallpox and arenaviruses is expecting big news and government orders.

Subscribers were alerted yesterday that a series of big government orders are anticipated to be announced "any day now," after sources confirmed to us that the official news and first purchase order could come within days.

SIGA Technologies, Inc. (NASDAQ:SIGA) has been trading up since late Thursday, when funds and others who were holding short positions started to cover in anticipation of this news.

The stock has a very, very low float and the price has been rising on just a little volume.  It is not unrealistic to think that the stock could soar and see $15 -$20 range on the news (based on our own technical analysis).

In May, SIGA announced that it had submitted its response to the Biomedical Advance Research and Development Authority (BARDA) regarding the agency's outstanding RFP for the procurement of 1.7 million courses of a smallpox antiviral.

The U.S. government considers the inhaled smallpox virus the single biggest biological threat which could be used against Americans via a terrorist attack.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).

Please learn more about the company here: http://www.siga.com/

Disclosure: No Positions





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 3 hours ago A Stem-Cell-Based Drug Gets Approval in Canada $OSIR http://t.co/XI3gAfMY
about 4 hours ago $JNJ Zytiga, a Prostate Cancer Drug, Does Well in Trial http://t.co/v7YUm9b6
about 5 hours ago $PFE Pfizer Lung Drug Stops Deadly Child Cancers in Study | http://t.co/hcfdrnCY
about 6 hours ago Human Genome Looks to Anyone but GlaxoSmithKline | http://t.co/d4IMkIn3
about 7 hours ago When David Einhorn did not mention Herbalife $HLF as a potential short candidate, that stock shot up on Wednesday | http://t.co/XpFKihQS
about 8 hours ago Stock Market: Stocks Get Hammered On Disappointing Data, Greece Worries http://t.co/FyH8zpru
about 8 hours ago Synergy Pharmaceuticals (SGYP) May Be Ready To Roll - Small Cap Stock Market Investing Tips http://t.co/FHYXlF1Q
about 11 hours ago Alvine Presents Results from Phase 2A Trial of ALV003 in Celiac Disease Patients -2012 Digestive Diseases Week Meeting http://t.co/e6Rjhbj9

navigation

Free Phone Trade Alerts

Benzinga.com supporter Seeking Alpha Certified